Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CD38 | P28907 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 5/20 | 0.41 |
| ▸ | BRAF | P15056 | 5/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729000 | 0.92 | FADS1 (0.55) | FADS1MAPKAPK2KDRCA9RAF1 | |
| SCHEMBL19729014 | 0.88 | MAPKAPK2 (0.45) | FADS1MAPKAPK2KDRCD38RAF1 | |
| SCHEMBL17845957 | 0.85 | CD38 (0.58) | FADS1CD38RAF1BRAFERBB2 | |
| SCHEMBL29793359 | 0.85 | CD38 (0.58) | FADS1CD38RAF1BRAFERBB2 | |
| SCHEMBL19729006 | 0.81 | CD38 (0.56) | MAPKAPK2KDRCD38RAF1BRAF | |
| SCHEMBL19729023 | 0.81 | FADS1 (0.58) | FADS1MAPKAPK2KDRCA9CD38 | |
| SCHEMBL19729026 | 0.80 | FADS1 (0.49) | FADS1MAPKAPK2KDRCA9CD38 | |
| SCHEMBL19729028 | 0.79 | MAPKAPK2 (0.61) | FADS1MAPKAPK2KDRCA9CD38 | |
| SCHEMBL19729033 | 0.78 | MAPKAPK2 (0.61) | FADS1MAPKAPK2CA9CD38RAF1 | |
| SCHEMBL19729010 | 0.77 | FADS1 (0.56) | FADS1MAPKAPK2KDRCA9RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | FADS1 4047/4885MAPKAPK2 156/4885KDR 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.